var data={"title":"Regulation of erythropoiesis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Regulation of erythropoiesis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/contributors\" class=\"contributor contributor_credentials\">Colin A Sieff, MB, BCh, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The production of erythrocytes is a tightly regulated process. During steady state hematopoiesis, approximately 10<sup>10</sup> red blood cells are produced per hour in the bone marrow to maintain the hemoglobin level within fairly narrow limits. Production can be rapidly increased in the setting of ongoing blood loss or hemolysis.</p><p>This topic review will discuss the elements that underlie erythropoiesis. A general discussion of hematopoiesis and stem cell function is presented separately. (See <a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">&quot;Overview of hematopoietic stem cells&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H50387\"><span class=\"h1\">OVERVIEW OF ERYTHROPOIESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythropoiesis begins with the differentiation of a small pool of multipotent stem cells into the most primitive erythroid progenitors. These progenitors develop into recognizable erythroid precursors, which subsequently follow a specific differentiation program that culminates in the emergence of mature erythrocytes. (See <a href=\"#H2\" class=\"local\">'Erythroid progenitor cells'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This process is driven by successive combinations of transcription factors that dictate the expression of adhesion and hematopoietic growth factor receptors (HGFRs). (See <a href=\"#H6\" class=\"local\">'Transcription factors'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adhesion receptors play an important role in the localization and release of maturing cells from specific niches in bone marrow. (See <a href=\"#H5\" class=\"local\">'Stroma'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematopoietic growth factors (HGFs), such as interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and Stem Cell Factor (SCF, also called Kit ligand or Steel factor), are important for the amplification of progenitor cells. (See <a href=\"#H11\" class=\"local\">'Growth factors'</a> below.)</p><p/><p>Erythropoietin (EPO) is a growth factor essential for the amplification and terminal differentiation of erythroid progenitors and precursors. Information concerning the control of EPO expression by hypoxia has provided new insight into the regulation of erythropoiesis. (See <a href=\"#H18\" class=\"local\">'Hypoxia and EPO expression'</a> below and <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera#H4\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;, section on 'Oxygen sensor'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ERYTHROID PROGENITOR CELLS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The erythroid progenitor compartment of the bone marrow is invisible upon inspection by light microscopy. These committed single lineage progenitors are derived from the stochastic differentiation of bipotential or multipotential progenitors, which emerged from a tiny population of stem cells (<a href=\"image.htm?imageKey=HEME%2F70092\" class=\"graphic graphic_figure graphicRef70092 \">figure 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/1\" class=\"abstract_t\">1</a>]. The two sets of erythroid progenitors (BFU-E and CFU-E) described below cannot be identified by specific morphological features, although they have been purified and analyzed using flow cytometric methods [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/2\" class=\"abstract_t\">2</a>]. Evidence suggests that all hematopoietic progenitors or stem cells resemble lymphoblasts [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p class=\"headingAnchor\" id=\"H11334197\"><span class=\"h2\">Erythroid burst-forming unit</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In humans, the most primitive single lineage committed erythroid progenitor is the erythroid burst-forming unit (BFU-E). These cellular clusters are so named because they have the following characteristics in semisolid in vitro cultures:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The colonies have a burst-like morphology.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In response to the combination of EPO and one of SCF, IL-3, or GM-CSF, the progeny of the first few cellular divisions are motile and form subpopulations of erythroid colony-forming units (CFU-E) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/6\" class=\"abstract_t\">6</a>]. Each of these units subsequently forms a large colony of proerythroblasts, which mature into erythroblasts and a few enucleated erythrocytes.</p><p/><p>The entire process requires approximately two weeks in vitro.</p><p class=\"headingAnchor\" id=\"H11334203\"><span class=\"h2\">Erythroid colony-forming unit</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone marrow also contains the more mature erythroid colony-forming unit (CFU-E) that, under the influence of EPO, form small colonies of erythroblasts in seven days of culture.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PRECURSORS AND MATURE CELLS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The erythroid precursor or erythroblast pool represents about one-third of the marrow cell population in the normal child (above the age of three) and the adult. Proerythroblasts are the earliest recognizable forms (<a href=\"image.htm?imageKey=HEME%2F68933\" class=\"graphic graphic_picture graphicRef68933 \">picture 1</a>). These cells divide and mature through basophilic, polychromatic, and orthochromatic normoblast cells to form the reticulocyte and finally to the circulating mature erythrocyte; this process involves a reduction in cell size, nuclear condensation and extrusion, and hemoglobin accumulation (<a href=\"image.htm?imageKey=HEME%2F55127\" class=\"graphic graphic_figure graphicRef55127 \">figure 2</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On average, each proerythroblast can form approximately eight reticulocytes. The mean transit time from proerythroblast to the emergence of the reticulocyte into the circulation is approximately five days [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the circulation, the reticulocyte takes approximately one day to become the mature erythrocyte (<a href=\"image.htm?imageKey=HEME%2F61552\" class=\"graphic graphic_figure graphicRef61552 \">figure 3</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The lifespan in the circulation of the mature erythrocyte is approximately four months. (See <a href=\"topic.htm?path=red-blood-cell-survival-normal-values-and-measurement#H5\" class=\"medical medical_review\">&quot;Red blood cell survival: Normal values and measurement&quot;, section on 'Determination of RBC lifespan'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Acute anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In acute anemia, the length of this transit time may decrease to as little as one or two days because of skipped divisions [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/8\" class=\"abstract_t\">8</a>]. In this setting, the red cells that emerge are macrocytic; they may also bear surface i antigen and other fetal characteristics, such as increased fetal hemoglobin (HbF), because they have had insufficient time to have converted i antigen to I antigen or to have acquired other adult characteristics [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/9\" class=\"abstract_t\">9</a>]. The cells also contain excessive burdens of the debris that normally accumulates during cell assembly [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. As a result, stress erythropoiesis is associated with circulating Pappenheimer bodies (iron granules), basophilic stippling (ribosomes), Heinz bodies (hemoglobin inclusions), and Howell-Jolly bodies (nuclear remnants) (<a href=\"image.htm?imageKey=HEME%2F71989%7EHEME%2F73790%7EHEME%2F60588\" class=\"graphic graphic_picture graphicRef71989 graphicRef73790 graphicRef60588 \">picture 2A-C</a>).</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">STROMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The bone marrow stroma consists of fibroblastoid cells, endothelial cells, and macrophages that comprise the hematopoietic microenvironment [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Interaction between receptors on erythrocyte precursors and elements of the stromal matrix are important determinants of erythroid maturation. As an example, murine erythroleukemia cells bind specifically to the extracellular matrix protein fibronectin [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/14\" class=\"abstract_t\">14</a>]; induction of differentiation of these cells subsequently leads to loss of adhesion. Binding to fibronectin involves very late antigen (VLA)-5, an erythroid integrin that is expressed on erythroid cells and is lost at the reticulocyte stage of development. VLA-5 binds to a specific peptide in the fibronectin molecule, Arg-Gly-Asp-Ser (RGDS) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Normal BFU-E bind preferentially to a stromal fibroblast cell strain [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/16\" class=\"abstract_t\">16</a>]; after binding, these cells proliferate and differentiate in the presence of EPO alone [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/16\" class=\"abstract_t\">16</a>]. This interaction is blocked by antibodies specific for the cell binding domain of fibronectin, which contains the RGDS sequence [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H2516876\"><span class=\"h2\">Macrophages</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Interactions between developing erythroid cells and macrophages are also important [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/17-22\" class=\"abstract_t\">17-22</a>]. This is classically exemplified by the &quot;erythroblastic island&quot;, composed of developing erythroblasts surrounding a central macrophage [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/22\" class=\"abstract_t\">22</a>]. These macrophages make physical contacts with developing erythroblasts, enabling signaling and the transfer of growth factors and nutrients (eg, iron) to these cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/23\" class=\"abstract_t\">23</a>].</p><p>Deoxyribonuclease II from these macrophages may be required for the process through which mature red cells lose their nuclei [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/24\" class=\"abstract_t\">24</a>]. In addition, Rac GTPases play an essential role in enucleation through activation of the formin mDia2, which nucleates unbranched actin filaments leading to formation of the contractile actin ring [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TRANSCRIPTION FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Much has been learned about the essential roles of several transcription factors via the study of their activation in leukemic translocations and the effect of gene disruption in embryonic stem cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/26\" class=\"abstract_t\">26</a>]. Important factors that most likely act at the level of hematopoietic stem cells include <span class=\"nowrap\">Tal-1/SCL,</span> <span class=\"nowrap\">Rbtn2/LMO2,</span> and GATA2, while GATA1, FOG1 and EKLF are more important for erythropoiesis (<a href=\"image.htm?imageKey=HEME%2F70092\" class=\"graphic graphic_figure graphicRef70092 \">figure 1</a>).</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Tal-1/SCL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><span class=\"nowrap\">Tal-1/SCL</span> is expressed in leukemias (biphenotypic <span class=\"nowrap\">[lymphoid/myeloid]</span> and T cell) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/27,28\" class=\"abstract_t\">27,28</a>], primitive hematopoietic progenitors, and more mature erythroid, mast, megakaryocyte, and endothelial cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Targeted disruption of this gene in mice leads to death in utero from the absence of blood formation. This finding, together with lack of in vitro myeloid colony formation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/31,32\" class=\"abstract_t\">31,32</a>], and data indicating that <span class=\"nowrap\">Tal-1/SCL</span> contribute to angiogenesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/33\" class=\"abstract_t\">33</a>], suggest a very early role for <span class=\"nowrap\">Tal-1/SCL,</span> most likely at the pluripotent or myeloid-erythroid stem cell level. Interestingly, conditional gene targeting in adult mice shows that <span class=\"nowrap\">Tal-1/SCL</span> is not required for engraftment and self-renewal of adult stem cells, but is required for differentiation of erythroid and megakaryocyte lineages [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/34\" class=\"abstract_t\">34</a>]. Overexpression of this factor in erythroid or bipotent cell lines produces an increase in erythroid differentiation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/35,36\" class=\"abstract_t\">35,36</a>], but there are no data on overexpression in adult hematopoietic stem cells.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Rbtn2/LMO2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Another transcription factor implicated in T cell acute lymphoblastic leukemia is the LIM-only domain nuclear protein rhombotin 2 <span class=\"nowrap\">(Rbtn2/LMO2)</span> [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/37,38\" class=\"abstract_t\">37,38</a>]. Mice that lack this factor die in utero and have the same bloodless phenotype as animals that lack <span class=\"nowrap\">Tal-1/SCL</span> [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/39\" class=\"abstract_t\">39</a>]. Although LMO2 does not show sequence specific DNA binding, immunoprecipitates in erythroid cells reveal that LMO2 exists in a complex with <span class=\"nowrap\">Tal-1/SCL</span> [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/40,41\" class=\"abstract_t\">40,41</a>], thereby suggesting a physiologic interaction in vivo.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">GATA2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GATA2 is expressed in the regions of Xenopus and Zebrafish embryos that are fated to become hematopoietic, and is highly expressed in progenitor cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/30,42-44\" class=\"abstract_t\">30,42-44</a>]. Overexpression of GATA2 in chicken erythroid progenitors leads to proliferation at the expense of differentiation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/45\" class=\"abstract_t\">45</a>].</p><p>On the other hand, targeted disruption of the <em>GATA2</em> gene leads to reduced primitive hematopoiesis in the yolk sac and embryonic death by day 10 to 11 [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/46\" class=\"abstract_t\">46</a>]. Definitive hematopoiesis in liver and bone marrow is profoundly reduced with loss of virtually all lineages, and in vitro differentiation data reveal a marked deficiency of SCF-responsive definitive erythroid and mast cell colonies and reduced macrophage colonies. This finding suggests that GATA2 serves as a regulator of genes that control hematopoietic growth factor responsiveness or proliferation of stem <span class=\"nowrap\">and/or</span> early progenitor cells.</p><p>The importance of GATA2 to hematopoiesis and lymphopoiesis has been brought into sharp focus by the discovery that heterozygous mutations in GATA2 are the cause of a broad spectrum of previously described syndromes including monocytopenia and non-tuberculous mycobacterial infections (monoMAC syndrome), dendritic cell, monocyte, B and NK lymphoid deficiency, familial myelodysplastic syndrome (MDS) and acute myeloid leukemia, and Emberger syndrome (lymphedema and MDS). In addition, susceptibility to human papilloma virus, chronic neutropenia, aplastic anemia, and pulmonary alveolar proteinosis have also been described [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=mendelian-susceptibility-to-mycobacterial-diseases-specific-defects#H3663155\" class=\"medical medical_review\">&quot;Mendelian susceptibility to mycobacterial diseases: Specific defects&quot;, section on 'GATA2 deficiency (MonoMAC syndrome)'</a> and <a href=\"topic.htm?path=nk-cell-deficiency-syndromes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;NK cell deficiency syndromes: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=congenital-neutropenia#H430729458\" class=\"medical medical_review\">&quot;Congenital neutropenia&quot;, section on 'MonoMAC syndrome'</a>.)</p><p>The finding of markedly decreased expression of GATA2 mRNA in CD34+ cells in patients with aplastic anemia suggests that an aberrant expression of this transcription factor may have been an early description of this disease [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/48\" class=\"abstract_t\">48</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">GATA1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GATA1 expression is limited to multipotent progenitors and to erythroid, megakaryocyte, mast, and eosinophil lineages [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/49-52\" class=\"abstract_t\">49-52</a>]. Analysis of chimeric mice injected at the blastocyst stage with <em>GATA1</em><sup><span class=\"nowrap\">-/-</sup></span> embryonic stem cells reveals a failure of such cells to contribute to erythrocyte development; however, they can contribute to other hematopoietic lineages and tissues [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Differentiation assays in vitro show proerythroblast arrest and apoptosis of these cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/55-57\" class=\"abstract_t\">55-57</a>].</p><p>Mouse embryos lacking GATA1 die because of severe anemia secondary to arrested maturation of primitive erythroid cells, while GATA1 loss in adult mice results in a condition resembling aplastic red blood cell crisis in humans [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Clinically, a constitutive mutation in <em>GATA1</em> that interferes with the interaction with its essential cofactor FOG1 (friend of GATA1) is associated with familial dyserythropoietic anemia, defective megakaryocyte maturation, and macrothrombocytopenia [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/59\" class=\"abstract_t\">59</a>]. Furthermore, in the context of trisomy 21, infants with Down syndrome (DS) and transient myeloproliferative disorder (TMD) or acute megakaryoblastic leukemia (AMKL) have acquired mutations in the 5' region of <em>GATA1</em> that lead to a N-terminal truncated GATA1 protein [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/60,61\" class=\"abstract_t\">60,61</a>]. These mutations are almost always present at birth, and therefore acquired in utero, and have also been noted in approximately 10 percent of neonates with DS and no evidence of TMD or AMKL [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/62\" class=\"abstract_t\">62</a>]. It remains to be seen whether such infants will go on to develop AMKL. (See <a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production#H23\" class=\"medical medical_review\">&quot;Anemia in children due to decreased red blood cell production&quot;, section on 'Congenital dyserythropoietic anemia'</a> and <a href=\"topic.htm?path=down-syndrome-clinical-features-and-diagnosis#H14\" class=\"medical medical_review\">&quot;Down syndrome: Clinical features and diagnosis&quot;, section on 'Hematologic disorders'</a> and <a href=\"topic.htm?path=megakaryocyte-biology-and-the-production-of-platelets#H9\" class=\"medical medical_review\">&quot;Megakaryocyte biology and the production of platelets&quot;, section on 'GATA-1 transcription factor'</a>.)</p><p>Interestingly, germ line mutations in <em>GATA1</em> that also lead to loss of exon 2 and truncation of the N-terminus of GATA1 were discovered in a small proportion of males with Diamond-Blackfan anemia. These mutations lead to synthesis of a short form of GATA1 that is impaired in its ability to drive erythroid differentiation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/63\" class=\"abstract_t\">63</a>]. Whether the more common ribosomal protein gene mutations that account for approximately 60 percent of cases are related in some way to GATA1 deficiency is an open question. (See <a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production#H3\" class=\"medical medical_review\">&quot;Anemia in children due to decreased red blood cell production&quot;, section on 'Diamond-Blackfan anemia'</a>.)</p><p>Whether precursor stem cells commit to erythroid or myeloid lineages may depend in part upon interactions between the GATA proteins (both GATA1 and GATA2) and PU.1 (Spi-1), a transcription factor essential for the development of myeloid cells. PU.1 appears to interact with a zinc finger domain of the GATA proteins via a helix-turn-helix wing [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/64\" class=\"abstract_t\">64</a>]; this interaction appears to inhibit PU.1 activation of critical myeloid genes, as well as GATA transactivating functions, thereby suggesting that these effects have a role in the commitment of cells to either the erythroid or myeloid lineage.</p><p class=\"headingAnchor\" id=\"H64529318\"><span class=\"h2\">Kr&#971;ppel-like factor 1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Kr&#971;ppel-like factor 1 (KLF1) transcription factor is a master regulator of terminal erythroid differentiation, controlling expression of many key erythroid pathways and structures, including cell division, the cell membrane and cytoskeleton, iron metabolism, and heme and globin synthesis. KLF1 was found to bind to the beta-globin promoter [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/65\" class=\"abstract_t\">65</a>]; it controls globin expression and some aspects of erythroid development. In addition to activating beta-globin expression, KLF1 plays a role in silencing gamma-globin expression, probably by regulating BCL11A and its interaction with Sox6 at the level of the gamma-globin gene [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/66-68\" class=\"abstract_t\">66-68</a>]. (See <a href=\"topic.htm?path=structure-and-function-of-normal-hemoglobins#H15\" class=\"medical medical_review\">&quot;Structure and function of normal hemoglobins&quot;, section on 'Fetal hemoglobin'</a> and <a href=\"topic.htm?path=fetal-hemoglobin-hemoglobin-f-in-health-and-disease#H6141716\" class=\"medical medical_review\">&quot;Fetal hemoglobin (hemoglobin F) in health and disease&quot;, section on 'Kruppel-like factor 1 (KLF1)'</a>.)</p><p>Heterozygous mutations in <em>KLF1</em> are characterized by hereditary persistence of fetal hemoglobin synthesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/66\" class=\"abstract_t\">66</a>] <span class=\"nowrap\">and/or</span> congenital dyserythropoietic anemia type IV [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/69\" class=\"abstract_t\">69</a>]. In contrast, compound heterozygous mutations of the <em>KLF1</em> gene have been associated with an unusual hereditary persistence of embryonic globin synthesis, as well as a wide variety of hematologic abnormalities including a thalassemic phenotype with hypochromia, microcytosis, target cells, fragments and anisopoikilocytosis; a picture suggestive of chronic non-spherocytic hemolytic anemia with schistocytes, fragmented cells and acanthocytes, and pyruvate kinase deficiency; and hydrops fetalis in a neonate with compound heterozygosity for null mutations in KLF1 [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/70-72\" class=\"abstract_t\">70-72</a>]. However, most monoallelic <em>KLF1</em> mutations give rise to benign phenotypes, including significant increases in levels of HbF and HbA2, which may ameliorate the clinical severity of beta thalassemia [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">GROWTH FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The regulation of the proliferation and maturation of erythroid progenitors depends upon interaction with a number of growth factors. The availability of pure recombinant growth factors, enrichment of target progenitor cells, use of defined &quot;serum-free&quot; culture conditions, and the targeted disruption of factors and their receptors have provided insights into the role of these factors during hematopoiesis.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Erythropoietin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythropoietin (EPO) is essential for the terminal maturation of erythroid cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/74\" class=\"abstract_t\">74</a>]. Its major effect appears to be at the level of the CFU-E during adult erythropoiesis; recombinant preparations are as effective as the natural hormone [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/75-78\" class=\"abstract_t\">75-78</a>]. (See <a href=\"topic.htm?path=treatment-of-anemia-in-nondialysis-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Treatment of anemia in nondialysis chronic kidney disease&quot;</a> and <a href=\"topic.htm?path=hyporesponse-to-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease\" class=\"medical medical_review\">&quot;Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease&quot;</a>.)</p><p>CFU-E do not survive in vitro in the absence of EPO. Since the majority of CFU-E are cycling, their survival in the presence of EPO may be tightly linked to their proliferation and differentiation to mature erythrocytes.</p><p>EPO also acts upon a subset of presumptive mature BFU-E, which requires EPO for survival and terminal maturation. A second subset of BFU-E, presumably less mature, survive EPO deprivation if other hematopoietic growth factors such as IL-3 or GM-CSF are present [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/79\" class=\"abstract_t\">79</a>].</p><p>Since EPO is crucial for the terminal differentiation of erythroid progenitors, mice with homozygous null mutations of the <em>EPO</em> or EPO receptor (<em>EPOR</em>) genes form BFU-E and CFU-E normally but these BFU-E and CFU-E fail to differentiate into mature erythrocytes [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/80\" class=\"abstract_t\">80</a>]. Both the <em>EPO</em><sup><span class=\"nowrap\">-/-</sup></span> and <em>EPOR</em><sup><span class=\"nowrap\">-/-</sup></span> mutations are embryonically lethal due to failure of definitive (fetal liver) erythropoiesis. However, yolk sac erythropoiesis is only partially impaired, indicating the existence of a population of EPO-independent primary erythropoietic precursors.</p><p>Insight into the molecular mechanism by which EPO prevents apoptosis in erythroid cells comes from studies of the signal transducer and activator of transcription 5 (STAT 5) proteins. <em>STAT5A</em><sup><span class=\"nowrap\">-/-</sup></span> <em>STAT5B</em><sup><span class=\"nowrap\">-/-</sup></span> mouse embryos are severely anemic during fetal development; the erythroid progenitors in fetal liver are reduced in number and show increased apoptosis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/81\" class=\"abstract_t\">81</a>]. This result was explained by the finding that STAT5 mediates the early induction of the anti-apoptotic gene <em>BCLXL</em> through direct binding to its promoter. Although adult animals were thought to be hematologically normal, about half have chronic anemia with splenomegaly, due to an increase in early erythroid precursors; erythropoiesis is ineffective because of an increase in apoptosis in early normoblasts showing reduced levels of BCLXL [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/82\" class=\"abstract_t\">82</a>]. In contrast, dominant gain-of-function mutations in the EPOR due to truncation of the cytoplasmic portion of the receptor lead to familial erythrocytosis (type 1) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/83\" class=\"abstract_t\">83</a>] because of elimination of the negative regulatory domain of the receptor that binds an inhibitory phosphatase SH-PTP-1 [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Insight into biased signaling downstream of the EPOR comes from study of a recessively inherited R150Q mutation of <em>EPO</em> [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/85\" class=\"abstract_t\">85</a>]. This mutation was found in a transfusion-dependent child thought initially to have Diamond-Blackfan anemia who unexpectedly did not experience improvement after a matched related hematopoietic stem cell transplant. The mutation results in alterations in the kinetics of binding of EPO to the EPOR, with an increased on-rate and a markedly increased off-rate. This results in suboptimal JAK2 phosphorylation, which is essential for STAT5 activation. Perhaps surprisingly, STAT5 activation by JAK2 showed equivalent phosphorylation in response to wild type and mutant EPO, whereas STAT1 and STAT3 activation were both reduced, indicating a bias in the signal output from the mutant receptor.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Stem Cell Factor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although Stem Cell Factor (SCF) alone has no colony-forming ability, it has marked synergistic effects on BFU-E cultured in the presence of EPO [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/86-89\" class=\"abstract_t\">86-89</a>]. SCF is crucial for the normal development of CFU-E, since mice that lack SCF (Steel mutants) or its receptor c-kit (White spotting or W mutants) are severely anemic and have a reduction in fetal liver CFU-E [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/90\" class=\"abstract_t\">90</a>]. Studies of cell lines that express both c-kit and EPOR (HCD57 cells) or are transduced with cDNAs for these two receptors (32D cells) demonstrate that SCF supports the proliferation of these cells only if the EPOR is also present [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/91\" class=\"abstract_t\">91</a>].</p><p>In vitro, SCF induces tyrosine phosphorylation of the EPOR and c-kit associates with the cytoplasmic domain of the tyrosine phosphorylated EPOR. Whether such an interaction between c-kit and the EPOR occurs during normal erythropoiesis is not known.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">IL-3 and GM-CSF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Interleukin 3 (IL-3) and GM-CSF receptors share a common beta chain. Both cytokines enhance erythropoietin-dependent in vitro erythropoiesis by primary hematopoietic progenitors and factor-dependent cells. The beta chain interacts functionally and physically with the EPOR, thereby providing an explanation for the synergistic effects of IL-3 and GM-CSF on EPO-driven erythropoiesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Insulin and insulin-like growth factor I</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Factors distinct from the classical colony-stimulating factors may positively regulate erythropoiesis, either directly or indirectly. Limiting dilution studies of highly purified CFU-E in serum-free culture show that insulin and insulin-like growth factor I act directly on these cells in the presence of EPO [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/93\" class=\"abstract_t\">93</a>]. By comparison, earlier murine studies of unfractionated cells found that CFU-E respond to IGF-I or insulin in the absence of EPO [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/94\" class=\"abstract_t\">94</a>].</p><p class=\"headingAnchor\" id=\"H24105025\"><span class=\"h2\">TGF-beta gene family</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This gene family comprises several TGF-beta and bone morphogenic proteins (BMPs), growth and differentiation factors (GDFs), and activin and inhibin. Their receptors comprise two members of the <span class=\"nowrap\">serine/threonine</span> kinase gene family. Activin enhances both BFU-E and CFU-E colony formation. This protein dimer, also known as follicle stimulating hormone-releasing protein, appears to have a lineage-specific effect on erythropoiesis that is indirect, since removal of monocytes <span class=\"nowrap\">and/or</span> T lymphocytes abrogates its activity [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/95\" class=\"abstract_t\">95</a>]. Activin is the factor produced by vegetal cells during blastogenesis that induces animal ectodermal cells to form primary mesoderm [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/96\" class=\"abstract_t\">96</a>].</p><p>Murine data suggest that TGF family members may play an intriguing regulatory role during erythropoiesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/97\" class=\"abstract_t\">97</a>]. Under normal circumstances, GDF11, produced by developing erythroid progenitor cells, inhibits the differentiation of more mature erythroid precursors. In thalassemia and myelodysplasia, ineffective erythropoiesis is markedly increased, with increased production of GDF11 and consequent decreased differentiation of erythroid cells.</p><p class=\"headingAnchor\" id=\"H582791\"><span class=\"h3\">Activin receptor ligand traps</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inhibition of erythroid differentiation by TGF-beta superfamily ligands can be abrogated in thalassemic mice by an activin receptor IIA (ActRIIA) ligand trap (RAP-011), which consists of the extracellular domain of the activin receptor 2A (ACVRIIA) linked to a murine immunoglobulin Fc domain [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/98\" class=\"abstract_t\">98</a>]. Treatment of animals with RAP-011 led to an increase in hemoglobin, improved ineffective erythropoiesis, and limited the iron overload which commonly accompanies ineffective erythropoiesis. An ActRIIB ligand trap (ACE-536) has also been used to achieve a similar improvement in anemia in myelodysplastic mice [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/99\" class=\"abstract_t\">99</a>].</p><p class=\"headingAnchor\" id=\"H582797\"><span class=\"h4\">Clinical utility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The above animal experiments derive from the original observation that sotatercept (ACE-011), a human ActRIIA ligand trap designed to improve bone mineral density in postmenopausal women by inhibiting activin-induced osteoclast mediated bone resorption, led to a surprising increase in hemoglobin and red cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/100,101\" class=\"abstract_t\">100,101</a>]. Sotatercept is being investigated in clinical trials for the improvement of anemia in individuals with Diamond-Blackfan anemia (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01464164?term=sotatercept&rank=1&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZlYCp3MTT2HHipPUzqGIum4Hcl49/PaKvHJaeC7f/14WrHe8PvBA3qtgak+jxfGj0Q=&amp;TOPIC_ID=7161\" target=\"_blank\" class=\"external\">NCT01464164</a>) as well as in individuals with end-stage renal disease on hemodialysis (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01146574?term=sotatercept&rank=3&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZnoBt9BqbetHD3/T1BIbAazHcl49/PaKvHJaeC7f/14WhO2tLdeRP5Bi5u8bWClXrI=&amp;TOPIC_ID=7161\" target=\"_blank\" class=\"external\">NCT01146574</a>).</p><p>A similar agent (ACE-536) has been shown in phase I studies to result in sustained increases in hemoglobin levels in healthy postmenopausal women [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/102\" class=\"abstract_t\">102</a>], and is being evaluated in phase II clinical trials for possible improvement of erythropoiesis in individuals with beta thalassemia (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01749540?term=ACE-536&rank=1&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZm1ztzc3zKeXakJwJjLq76DXrB1z7svGLR2VwkJQlVWb9loGjItRLDSyfPeoc+rnj0=&amp;TOPIC_ID=7161\" target=\"_blank\" class=\"external\">NCT01749540</a>) and myelodysplastic syndromes (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01749514?term=ACE-536&rank=3&amp;token=YbJELcAW9G3aZfZrjTwgljvGy8B5W5sYbMw5bZWXTZnvSWQuYUPD/rADKtOE43X4q2lh+5JkfkXONIxmqmcwuvws+CAHSsm4ZiBziP5WjP4=&amp;TOPIC_ID=7161\" target=\"_blank\" class=\"external\">NCT01749514</a>), presumably by binding with ligands in the TGF-beta superfamily and promoting late-stage erythroid differentiation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/103\" class=\"abstract_t\">103</a>]. (See <a href=\"topic.htm?path=management-and-prognosis-of-the-thalassemias#H146416304\" class=\"medical medical_review\">&quot;Management and prognosis of the thalassemias&quot;, section on 'Drug therapies under investigation'</a>.)</p><p class=\"headingAnchor\" id=\"H1280406\"><span class=\"h1\">MicroRNAs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MicroRNAs (miRNAs) are 18 to 25 nucleotide non-protein encoding RNAs that play important roles in the regulation of post transcriptional gene expression. After RNA polymerase II mediated transcription, the primary hairpin transcript (pri-miRNA) is processed in the nucleus by Drosha and DGCR8 into pre-miRNA, which is exported into the cytoplasm. Pre-miRNA is further processed by <span class=\"nowrap\">Dicer/TAR</span> RNA binding protein, and one strand of the duplex is degraded while the other is incorporated into the RNA-induced silencing complex (RISC) that contains the Argonaute proteins. The miRNA strand guides RISC typically to complementary sequences in the 3&rsquo; untranslated region of target mRNA by Watson Crick base-pairing, and leads to either mRNA degradation or translational repression.</p><p>There is strong evidence that miRNAs are important for erythropoiesis. Many miRNAs are expressed in developing erythroid cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/104,105\" class=\"abstract_t\">104,105</a>]; most appear to decline in expression level as precursors mature, suggesting that they might regulate the timing of genes important for the synthesis of late erythroid proteins. For example, miR-191 is downregulated, and overexpression in mouse fetal liver cells results in a block in enucleation, a late event in erythropoiesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/106\" class=\"abstract_t\">106</a>]. As expected, two miR-191 target genes identified in this study, Riok3 and Mxi1, are upregulated during erythropoiesis. Knockdown of these genes led to a similar block in enucleation. Other miRNAs that decrease in expression during differentiation act at an earlier stage of erythropoiesis. Both miR-221 and miR-222 are encoded on a common pre-miRNA; they target and repress KIT expression, so overexpression impairs the proliferation of erythroid precursors [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/107\" class=\"abstract_t\">107</a>]. miR-223 targets LMO2 mRNA (see <a href=\"#H8\" class=\"local\">'Rbtn2/LMO2'</a> above), and overexpression leads to a block in CD34 cell proliferation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/108,109\" class=\"abstract_t\">108,109</a>]. miR-150 appears to regulate MYB levels critical for lineage commitment of bipotential megakaryocyte-erythroid progenitors (MEP). Overexpression of miR-150 leads to a decrease in MYB levels that then drives megakaryocyte at the expense of erythroid differentiation. Interestingly, thrombopoietin (TPO) induces miR-150 expression, suggesting another mechanism by which TPO induces megakaryocyte production [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/108,109\" class=\"abstract_t\">108,109</a>].</p><p>Other miRNAs, such as miR-144 and miR-451, increase in expression level during erythropoiesis; both are co-expressed in a bi-cistronic pri-miRNA that is activated by GATA1 [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/110\" class=\"abstract_t\">110</a>]. Enforced expression of these two miRs enhances erythropoiesis while depletion of miR-451 has the opposite effect [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/104,111\" class=\"abstract_t\">104,111</a>]. GATA2 is a target of miR-451 in zebrafish [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/112\" class=\"abstract_t\">112</a>], and since down-regulation of GATA2 is required for normal erythropoiesis, this might explain the effect of miR-451 depletion. Other experiments suggest that the <span class=\"nowrap\">miR-144/451</span> effect is more complex, and different mouse models show different phenotypes ranging from an erythroblast block [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/113\" class=\"abstract_t\">113</a>] to a hemolytic anemia with an increase in reticulocytes [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/114\" class=\"abstract_t\">114</a>]. The differences in phenotype may lie in the degree of oxidative stress produced in these animals, as exposure to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) leads to increased accumulation of reactive oxygen species in <span class=\"nowrap\">miR144/451<sup>-/-</sup></span> erythroid cells. These cells have a reduction in the accumulation of nuclear FoxO3, a transcription factor that is a master regulator of anti-oxidant responses. There is evidence that one of the major targets of miR-451 is 14-3-3zeta, a <span class=\"nowrap\">phosphoserine/phosphothreonine</span> binding protein that negatively regulates FoxO3 by localizing it to the cytoplasm.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">HYPOXIA AND EPO EXPRESSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EPO has long been recognized as the physiologic regulator of red cell production [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/115-118\" class=\"abstract_t\">115-118</a>]. It is produced in the kidney and the fetal liver in response to hypoxia or exposure to cobalt chloride.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Hypoxia-inducible factor and the response to hypoxia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Specialized interstitial cells in the inner cortex and outer medulla of the kidney respond to hypoxia by producing and secreting EPO. Downstream events from the oxygen sensor involved in activation of EPO gene expression require stabilization and activation of specific transcription factors [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/119\" class=\"abstract_t\">119</a>]. One of these is the heterodimeric transcription factor complex hypoxia-inducible factor (HIF-1), comprising both HIF-1-alpha and HIF-1-beta subunits (the dimer is called HIF-1) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/119-122\" class=\"abstract_t\">119-122</a>].</p><p>While HIF-1-beta is ubiquitously expressed independent of oxygen tension, HIF-1-alpha is only detectable under hypoxic conditions (<a href=\"image.htm?imageKey=HEME%2F53801\" class=\"graphic graphic_figure graphicRef53801 \">figure 4</a>). Above a critical oxygen concentration HIF-1-alpha is ubiquitinated and rapidly degraded in proteosomes. This oxygen sensor in mammalian cells appears to be a proline hydroxylase (prolyl hydroxylase domain proteins PHD1, PHD2, and PHD3) that adds a hydroxyl moiety in an oxygen- and iron-dependent manner to P-564 of HIF-1-alpha; P-564 lies within a highly conserved region of HIF-1-alpha that binds the von Hippel-Lindau (VHL) protein. When P-564 hydroxylated HIF-1-alpha binds VHL, an ubiquitin E3 ligase complex is activated, leading to ubiquitination and subsequent destruction of HIF-1-alpha [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/119,123-129\" class=\"abstract_t\">119,123-129</a>]. A second related protein, HIF-2-alpha, is also subject to oxygen dependent prolyl hydroxylation, and also dimerizes with HIF-1-beta to form HIF-2. HIF-1-alpha is expressed in all nucleated cells, while HIF-2-alpha expression is restricted to vascular endothelial cells, renal interstitial cells, hepatocytes, cardiomyocytes and astrocytes [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/119\" class=\"abstract_t\">119</a>].</p><p>A homozygous R200W mutation of the <em>VHL</em> gene leads to reduction in the interaction of VHL with hydroxylated HIF, accumulation of HIF, and excessive erythrocyte production in Chuvash polycythemia (familial erythrocytosis, type 2) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/130\" class=\"abstract_t\">130</a>]. A different set of dominantly inherited mutations is found in the von Hippel-Lindau syndrome, with loss of the second normal allele in the tumors that characterize this disease. (See <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera#H10\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;, section on 'von Hippel Lindau gene mutation'</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia#H24\" class=\"medical medical_review\">&quot;Diagnostic approach to the patient with polycythemia&quot;, section on 'Tumor polycythemia'</a> and <a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease\" class=\"medical medical_review\">&quot;Molecular biology and pathogenesis of von Hippel-Lindau disease&quot;</a>.)</p><p>An autosomal dominant form of erythrocytosis occurs with mutations the EGLN1 gene that encodes PHD2 (familial erythrocytosis, type 3) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/131\" class=\"abstract_t\">131</a>]. These mutations may have dominant negative effects because PHD2<sup><span class=\"nowrap\">+/-</sup></span> heterozygous mice do not have erythrocytosis.</p><p>Additionally, mutations in the <em>EPAS1</em> gene that encodes HIF-2-alpha can also cause familial erythrocytosis (type 4) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/132\" class=\"abstract_t\">132</a>]. These mutations interfere with the interaction of HIF-2-alpha with PHD2, thereby reducing hydroxylation. Mice with targeted disruption of the <em>EPAS1</em> gene are anemic, emphasizing the importance of HIF-2-alpha in EPO regulation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/133\" class=\"abstract_t\">133</a>].</p><p>HIF-1 activity is induced in a variety of cell types in response to hypoxia or cobalt [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/134\" class=\"abstract_t\">134</a>]; this finding suggests that, while HIF-1 is important in the activation of EPO expression, it also plays a role in the activation of other hypoxia-inducible genes, including angiogenesis and glycolysis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/120,135-137\" class=\"abstract_t\">120,135-137</a>], and may play a role in the regulation of more than 2 percent of all human genes [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/138\" class=\"abstract_t\">138</a>]. HIF-1-alpha may also bind to and negatively regulate the hepcidin promoter, leading to decreased levels of hepcidin [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/139\" class=\"abstract_t\">139</a>]. Through coordinate downregulation of hepcidin and upregulation of ferroportin and erythropoietin, the VHL pathway effectively mobilizes iron in support of increased red cell production. (See <a href=\"topic.htm?path=regulation-of-iron-balance#H16\" class=\"medical medical_review\">&quot;Regulation of iron balance&quot;, section on 'Hepcidin'</a>.)</p><p>The activity of HIF-1 is essential for survival. Mice that lack HIF-1 die at midgestation, while heterozygotes, although developmentally normal and similar to normal mice in normoxic conditions, fail to respond adequately to chronic hypoxia [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/140\" class=\"abstract_t\">140</a>]. (See <a href=\"topic.htm?path=overview-of-angiogenesis-inhibitors#H4\" class=\"medical medical_review\">&quot;Overview of angiogenesis inhibitors&quot;, section on 'Effect of hypoxia and cytokines'</a>.)</p><p>HIF-1 binds to an enhancer sequence located approximately 130 base pairs downstream from the poly-A addition signal of the EPO gene. This enhancer segment renders other promoter-reporter gene constructs hypoxia-responsive with typical inductions in the range of 4 to 15 fold; this degree of stimulation is significantly less than the 50 to 100 fold induction observed with the chromosomal EPO gene in Hep 3B cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/141\" class=\"abstract_t\">141</a>].</p><p>Other studies have identified a 53 base pair sequence in the EPO promoter with important regulatory characteristics. This sequence confers oxygen-sensitivity (6 to 10-fold inducibility) to a luciferase reporter gene [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/142\" class=\"abstract_t\">142</a>]. The combination of both the enhancer and promoter sequences results in cooperative (50-fold) inducibility of transcription of EPO in response to hypoxia, enhancements approaching that observed in vivo.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Hepatocyte nuclear factor 4 and p300</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because both promoter and enhancer sequence elements include the consensus hexanucleotide nuclear hormone receptor response elements, various orphan members of this gene family have been examined for binding to the <em>EPO </em>promoter and enhancer and for their presence in transcription complexes isolated from Hep 3B nuclear extracts. One of these, hepatocyte nuclear factor 4 (HNF-4) is present in these extracts and plays a critical role in hypoxia-induced activation of EPO gene expression in Hep 3B cells [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/143\" class=\"abstract_t\">143</a>]. HIF-1a and -1b also bind to a large protein p300 (homologous to the cyclic AMP response element (CREB) binding protein [CBP]) that acts as a general transcriptional activator for a number of genes [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/144\" class=\"abstract_t\">144</a>].</p><p>The net effect is that HIF-1a, which accumulates in response to hypoxia, combines with its partner HIF-1b and with HNF-4 and p300 to activate EPO transcription. The role of HIF-2 in this process is under active investigation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/145\" class=\"abstract_t\">145</a>]. (See <a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera#H12\" class=\"medical medical_review\">&quot;Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera&quot;, section on 'EPAS1 (hypoxia inducible factor 2) gene mutations'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">STRESS AND ERYTHROPOIESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The level of oxyhemoglobin and the rate of delivery of oxygen to the tissues are the fundamental regulators of erythropoiesis (<a href=\"image.htm?imageKey=HEME%2F53916\" class=\"graphic graphic_figure graphicRef53916 \">figure 5</a>) [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/146\" class=\"abstract_t\">146</a>]. In species that package hemoglobin in erythrocytes, erythropoietin mediates the response to oxygen demand; it performs this function by interacting with specific receptors that are found on the surface of committed erythroid progenitor cells and erythroblasts [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/147-151\" class=\"abstract_t\">147-151</a>]. As noted above, hypoxia induces a transcriptional increase in expression of the EPO gene via HIF-1a and HIF-1b [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/120,121\" class=\"abstract_t\">120,121</a>].</p><p>In vivo, BFU-E do not give rise to erythroblasts except under conditions of <strong>extreme</strong> anemic stress. Instead, they mature to single CFU-E; in vivo, CFU-E divide and, under the influence of lower concentrations of erythropoietin, form single, relatively small colonies of proerythroblasts at about one week in vitro.</p><p>The bone marrow of an adult mouse contains about 500 CFU-E per 10<sup>5</sup> nucleated cells. In response to anemic stress, as in hemorrhage or hemolysis, almost the entire burden of accelerated reticulocyte production is borne by the rapid erythropoietin-dependent influx from the progenitor compartment into the proerythroblast pool, resulting in an expanded proerythroblast pool [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/152\" class=\"abstract_t\">152</a>].</p><p>Anemic stress produces little or no increase in the mitotic rate of recognizable erythroid precursors [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/152\" class=\"abstract_t\">152</a>]. Instead, the following changes are seen:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The late BFU-E and CFU-E proliferate (because of EPO binding to its receptors) and differentiate to proerythroblasts and beyond. In normal murine marrow, the CFU-E frequency increases from about 500 per 10<sup>5</sup> nucleated cells to 1000 to 2000 CFU-E per 10<sup>5</sup> nucleated cells following experimental hemorrhage or hemolysis. By comparison, hypertransfused mice, in which erythropoiesis is completely suppressed, show an 80 to 90 percent reduction in number of CFU-E.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The orderly progression from immature BFU-E through CFU-E to proerythroblast is interrupted. High erythropoietin levels permit or induce differentiation of immature progenitors to proerythroblasts. In the rhesus monkey, this premature terminal differentiation may account for the marked increase in fetal hemoglobin content and F cells observed during stress erythropoiesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/153\" class=\"abstract_t\">153</a>]. In contrast, progenitors in humans have a lesser ability to generate erythroblasts capable of synthesizing large quantities of fetal hemoglobin [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/154\" class=\"abstract_t\">154</a>]. As a result, the accumulation of F cells in peripheral blood in response to anemia is relatively small [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/155\" class=\"abstract_t\">155</a>]. (See <a href=\"topic.htm?path=fetal-hemoglobin-hemoglobin-f-in-health-and-disease#H230492\" class=\"medical medical_review\">&quot;Fetal hemoglobin (hemoglobin F) in health and disease&quot;, section on 'Acquired increases in HbF'</a>.)</p><p/><p>Red cells produced under such situations are usually macrocytic and carry the i antigen. However, these two characteristics may relate to a short transit time through the marrow in response to erythropoietin rather than an intrinsic characteristic of fetal hemoglobin-containing cells themselves. Fetal hemoglobin-containing cells (F cells) are also present in very small numbers in the blood of normal individuals, but these cells are not macrocytic and do not bear i antigen. F cell progenitors can be easily detected in the bone marrow of patients with various dyspoieses [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/156,157\" class=\"abstract_t\">156,157</a>] and even in normal marrows [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/158\" class=\"abstract_t\">158</a>].</p><p>In mice, stress erythropoiesis appears to occur largely in the spleen, where &quot;stress&quot; BFU-E respond to EPO, SCF, and bone morphogenic protein 4 (BMP4), which signals via the smad5 pathway; hypoxia increases both BMP expression and the <span class=\"nowrap\">BMP4/smad5</span> signaling response [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/159\" class=\"abstract_t\">159</a>]. This contrasts with &quot;steady state&quot; bone marrow BFU-E that require only SCF, <span class=\"nowrap\">IL-3/GM-CSF</span> and become responsive to EPO as they mature to CFU-E and proerythroblasts. There is also evidence that Hedgehog signaling replenishes splenic stress BFU-E from the bone marrow BFU-E pool [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/160\" class=\"abstract_t\">160</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">NEGATIVE REGULATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In humans, subsets of lymphocytes with a suppressor phenotype may inhibit erythroid activity in vitro [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/161-163\" class=\"abstract_t\">161-163</a>]. This finding is consistent with reports of patients in whom anemia or granulocytopenia is associated with an expansion of certain T lymphocyte populations [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/164-168\" class=\"abstract_t\">164-168</a>]. In the rare disorder named T lymphocytosis with cytopenia, in vitro suppression of erythropoiesis correlates with expansion of a T lymphocyte population; these cells may be the counterpart of the hematopoietic suppressor cells isolated from normal blood [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/169\" class=\"abstract_t\">169</a>].</p><p>The phenotype of this T suppressor cell has been described in detail [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/169,170\" class=\"abstract_t\">169,170</a>]. The cell is a large granular lymphocyte that is both E rosette-positive and CD8 (classic suppressor phenotype)-positive. Such suppressor T cells may also be involved in some cases of aplastic anemia [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/171,172\" class=\"abstract_t\">171,172</a>], neutropenia without an underlying immunologic disorder, or overt T cell proliferation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/173\" class=\"abstract_t\">173</a>].</p><p>It is unknown exactly how these suppressor T cells interact with hematopoietic progenitors, and what surface antigens are &quot;seen&quot; by the suppressor cells. Suppression of erythroid colony expression in vitro may be regulated by T cells in a genetically restricted fashion [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/170,174\" class=\"abstract_t\">170,174</a>]. Cell-cell interactions in immunologic systems have been well characterized with regard to surface determinants that permit cellular recognition. The observation that hematopoietic progenitors have a unique distribution of class II histocompatibility antigens on their cell surface suggests a role for these antigens in the cell-cell interactions that regulate hematopoietic differentiation [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/175-177\" class=\"abstract_t\">175-177</a>].</p><p>T cells may also inhibit erythropoiesis via the production of inhibitory cytokines. Some lymphokines may inhibit erythropoiesis in vitro via a complex lymphokine cascade:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Activation of T cells by the T cell antigen receptor CD3 results in cell surface expression of the interleukin (IL)-2 receptor alpha chain and the acquisition of IL-2 responsiveness [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/178\" class=\"abstract_t\">178</a>]. IL-2 inhibits BFU-E in the presence of these IL-2 R positive cells, possibly by inducing their release of interferon (IFN)-gamma, a known suppressor of erythropoiesis [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/179,180\" class=\"abstract_t\">179,180</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CD2 can serve as an alternative pathway of T cell activation, via binding to its ligand, LFA-3, on antigen-presenting cells. Blockade of CD2 with monoclonal antibody leads to abrogation of <span class=\"nowrap\">IL-2/IFN-gamma</span> mediated BFU-E suppression [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/181\" class=\"abstract_t\">181</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor necrosis factor also suppresses erythropoiesis in vitro [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/182,183\" class=\"abstract_t\">182,183</a>]. Evidence for this is derived from studies in Friend murine leukemia virus infected animals in which the injection of peritoneal macrophages results in rapid but transient resolution of the massive erythroid hyperplasia associated with this disease. This effect may be due to elaboration by macrophages of IL-1-alpha, which acts via induction of tumor necrosis factor. Macrophage-mediated inhibition of erythropoiesis is reversed by EPO [<a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/184\" class=\"abstract_t\">184</a>].</p><p/><p class=\"headingAnchor\" id=\"H20133062\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythropoiesis begins with the differentiation of a small pool of multipotent stem cells into primitive erythroid progenitors. These develop into erythroid precursors, culminating in the emergence of mature erythrocytes. (See <a href=\"#H2\" class=\"local\">'Erythroid progenitor cells'</a> above and <a href=\"#H3\" class=\"local\">'Precursors and mature cells'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The erythroid maturation process is driven by transcription factors as well as hematopoietic growth factors and their receptors (<a href=\"image.htm?imageKey=HEME%2F70092\" class=\"graphic graphic_figure graphicRef70092 \">figure 1</a> and <a href=\"image.htm?imageKey=HEME%2F55127\" class=\"graphic graphic_figure graphicRef55127 \">figure 2</a>). (See <a href=\"#H6\" class=\"local\">'Transcription factors'</a> above and <a href=\"#H11\" class=\"local\">'Growth factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythropoietin (EPO) is the physiologic regulator of red cell production, produced in the kidney and the fetal liver in response to hypoxia due to anemia or other causes (<a href=\"image.htm?imageKey=HEME%2F53801\" class=\"graphic graphic_figure graphicRef53801 \">figure 4</a> and <a href=\"image.htm?imageKey=HEME%2F53916\" class=\"graphic graphic_figure graphicRef53916 \">figure 5</a>). (See <a href=\"#H12\" class=\"local\">'Erythropoietin'</a> above and <a href=\"#H18\" class=\"local\">'Hypoxia and EPO expression'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A general discussion of hematopoiesis and stem cell function is presented separately. (See <a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">&quot;Overview of hematopoietic stem cells&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/1\" class=\"nounderline abstract_t\">Suda T, Suda J, Ogawa M. Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci U S A 1984; 81:2520.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/2\" class=\"nounderline abstract_t\">Li J, Hale J, Bhagia P, et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. Blood 2014; 124:3636.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/3\" class=\"nounderline abstract_t\">Emerson SG, Sieff CA, Wang EA, et al. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest 1985; 76:1286.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/4\" class=\"nounderline abstract_t\">Dicke KA, van Noord MJ, Maat B, et al. Identification of cells in primate bone marrow resembling the hemopoietic stem cell in the mouse. Blood 1973; 42:195.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/5\" class=\"nounderline abstract_t\">Rosse C. Small lymphocyte and transitional cell populations of the bone marrow; their role in the mediation of immune and hemopoietic progenitor cell functions. Int Rev Cytol 1976; 45:155.</a></li><li class=\"breakAll\">Axelrad AA, McLeod DL, et al. Properties of cells that produce erythrocytic colonies in vitro. In: Hematopoiesis in Culture, Robinson, WA (Eds), National Institutes of Health, Washington 1974. p.226.</li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/7\" class=\"nounderline abstract_t\">Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49:17.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/8\" class=\"nounderline abstract_t\">Lord BI. Kinetics of the recognizable erythrocyte precursor cells. Clin Haematol 1979; 8:355.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/9\" class=\"nounderline abstract_t\">Hillman RS, Giblett ER. Red cell membrane alteration associated with &quot;marrow stress&quot;. J Clin Invest 1965; 44:1730.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/10\" class=\"nounderline abstract_t\">Nathan DG. Rubbish in the red cell. N Engl J Med 1969; 281:558.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/11\" class=\"nounderline abstract_t\">Etlinger JD, Goldberg AL. Control of protein degradation in reticulocytes and reticulocyte extracts by hemin. J Biol Chem 1980; 255:4563.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/12\" class=\"nounderline abstract_t\">M&uuml;ller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells 1995; 13:477.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/13\" class=\"nounderline abstract_t\">Clark BR, Keating A. Biology of bone marrow stroma. Ann N Y Acad Sci 1995; 770:70.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/14\" class=\"nounderline abstract_t\">Patel VP, Lodish HF. Loss of adhesion of murine erythroleukemia cells to fibronectin during erythroid differentiation. Science 1984; 224:996.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/15\" class=\"nounderline abstract_t\">Patel VP, Lodish HF. The fibronectin receptor on mammalian erythroid precursor cells: characterization and developmental regulation. J Cell Biol 1986; 102:449.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/16\" class=\"nounderline abstract_t\">Tsai S, Patel V, Beaumont E, et al. Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin. Blood 1987; 69:1587.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/17\" class=\"nounderline abstract_t\">Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996; 87:2513.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/18\" class=\"nounderline abstract_t\">Sadahira Y, Yoshino T, Monobe Y. Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J Exp Med 1995; 181:411.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/19\" class=\"nounderline abstract_t\">Yanai N, Sekine C, Yagita H, Obinata M. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 1994; 83:2844.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/20\" class=\"nounderline abstract_t\">Rhodes MM, Kopsombut P, Bondurant MC, et al. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood 2008; 111:1700.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/21\" class=\"nounderline abstract_t\">Chow A, Huggins M, Ahmed J, et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med 2012; 19:429.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/22\" class=\"nounderline abstract_t\">Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood 2008; 112:470.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/23\" class=\"nounderline abstract_t\">Korolnek T, Hamza I. Macrophages and iron trafficking at the birth and death of red cells. Blood 2015; 125:2893.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/24\" class=\"nounderline abstract_t\">Kawane K, Fukuyama H, Kondoh G, et al. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 2001; 292:1546.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/25\" class=\"nounderline abstract_t\">Ji P, Murata-Hori M, Lodish HF. Formation of mammalian erythrocytes: chromatin condensation and enucleation. Trends Cell Biol 2011; 21:409.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/26\" class=\"nounderline abstract_t\">Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/27\" class=\"nounderline abstract_t\">Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A 1989; 86:2031.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/28\" class=\"nounderline abstract_t\">Finger LR, Kagan J, Christopher G, et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci U S A 1989; 86:5039.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/29\" class=\"nounderline abstract_t\">Begley CG, Aplan PD, Denning SM, et al. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A 1989; 86:10128.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/30\" class=\"nounderline abstract_t\">Mouthon MA, Bernard O, Mitjavila MT, et al. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood 1993; 81:647.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/31\" class=\"nounderline abstract_t\">Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 1995; 373:432.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/32\" class=\"nounderline abstract_t\">Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A 1995; 92:7075.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/33\" class=\"nounderline abstract_t\">Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev 1998; 12:473.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/34\" class=\"nounderline abstract_t\">Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 2003; 421:547.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/35\" class=\"nounderline abstract_t\">Aplan PD, Nakahara K, Orkin SH, Kirsch IR. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J 1992; 11:4073.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/36\" class=\"nounderline abstract_t\">Hoang T, Paradis E, Brady G, et al. Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation. Blood 1996; 87:102.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/37\" class=\"nounderline abstract_t\">Boehm T, Foroni L, Kaneko Y, et al. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 1991; 88:4367.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/38\" class=\"nounderline abstract_t\">Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/39\" class=\"nounderline abstract_t\">Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78:45.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/40\" class=\"nounderline abstract_t\">Valge-Archer VE, Osada H, Warren AJ, et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci U S A 1994; 91:8617.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/41\" class=\"nounderline abstract_t\">Wadman I, Li J, Bash RO, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J 1994; 13:4831.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/42\" class=\"nounderline abstract_t\">Dorfman DM, Wilson DB, Bruns GA, Orkin SH. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem 1992; 267:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/43\" class=\"nounderline abstract_t\">Leonard M, Brice M, Engel JD, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation. Blood 1993; 82:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/44\" class=\"nounderline abstract_t\">Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993; 82:1493.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/45\" class=\"nounderline abstract_t\">Briegel K, Lim KC, Plank C, et al. Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. Genes Dev 1993; 7:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/46\" class=\"nounderline abstract_t\">Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371:221.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/47\" class=\"nounderline abstract_t\">Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/48\" class=\"nounderline abstract_t\">Fujimaki S, Harigae H, Sugawara T, et al. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol 2001; 113:52.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/49\" class=\"nounderline abstract_t\">Martin DI, Zon LI, Mutter G, Orkin SH. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 1990; 344:444.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/50\" class=\"nounderline abstract_t\">Romeo PH, Prandini MH, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 1990; 344:447.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/51\" class=\"nounderline abstract_t\">Zon LI, Yamaguchi Y, Yee K, et al. Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription. Blood 1993; 81:3234.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/52\" class=\"nounderline abstract_t\">Zheng J, Kitajima K, Sakai E, et al. Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood 2006; 107:520.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/53\" class=\"nounderline abstract_t\">Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349:257.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/54\" class=\"nounderline abstract_t\">Simon MC, Pevny L, Wiles MV, et al. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet 1992; 1:92.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/55\" class=\"nounderline abstract_t\">Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/56\" class=\"nounderline abstract_t\">Pevny L, Lin CS, D'Agati V, et al. Development of hematopoietic cells lacking transcription factor GATA-1. Development 1995; 121:163.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/57\" class=\"nounderline abstract_t\">Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A 1995; 92:9623.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/58\" class=\"nounderline abstract_t\">Guti&eacute;rrez L, Tsukamoto S, Suzuki M, et al. Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood 2008; 111:4375.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/59\" class=\"nounderline abstract_t\">Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24:266.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/60\" class=\"nounderline abstract_t\">Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/61\" class=\"nounderline abstract_t\">Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101:4301.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/62\" class=\"nounderline abstract_t\">Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103:2480.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/63\" class=\"nounderline abstract_t\">Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/64\" class=\"nounderline abstract_t\">Zhang P, Behre G, Pan J, et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci U S A 1999; 96:8705.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/65\" class=\"nounderline abstract_t\">Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kr&uuml;ppel family of nuclear proteins. Mol Cell Biol 1993; 13:2776.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/66\" class=\"nounderline abstract_t\">Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010; 42:801.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/67\" class=\"nounderline abstract_t\">Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010; 42:742.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/68\" class=\"nounderline abstract_t\">Tallack MR, Perkins AC. Three fingers on the switch: Kr&uuml;ppel-like factor 1 regulation of &gamma;-globin to &beta;-globin gene switching. Curr Opin Hematol 2013; 20:193.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/69\" class=\"nounderline abstract_t\">Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 2010; 87:721.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/70\" class=\"nounderline abstract_t\">Viprakasit V, Ekwattanakit S, Riolueang S, et al. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood 2014; 123:1586.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/71\" class=\"nounderline abstract_t\">Satta S, Perseu L, Maccioni L, et al. Delayed fetal hemoglobin switching in subjects with KLF1 gene mutation. Blood Cells Mol Dis 2012; 48:22.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/72\" class=\"nounderline abstract_t\">Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. Blood 2015; 125:2405.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/73\" class=\"nounderline abstract_t\">Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of &beta;-thalassemia. Blood 2014; 124:803.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/74\" class=\"nounderline abstract_t\">Malik J, Kim AR, Tyre KA, et al. Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts. Haematologica 2013; 98:1778.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/75\" class=\"nounderline abstract_t\">Sieff CA, Emerson SG, Mufson A, et al. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest 1986; 77:74.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/76\" class=\"nounderline abstract_t\">Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/77\" class=\"nounderline abstract_t\">Eaves AC, Eaves CJ. Erythropoiesis in culture. Clin Haematol 1984; 13:371.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/78\" class=\"nounderline abstract_t\">Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/79\" class=\"nounderline abstract_t\">Sieff CA, Ekern SC, Nathan DG, Anderson JW. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood 1989; 73:688.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/80\" class=\"nounderline abstract_t\">Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/81\" class=\"nounderline abstract_t\">Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/82\" class=\"nounderline abstract_t\">Socolovsky M, Nam H, Fleming MD, et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001; 98:3261.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/83\" class=\"nounderline abstract_t\">de la Chapelle A, Tr&auml;skelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993; 90:4495.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/84\" class=\"nounderline abstract_t\">Klingm&uuml;ller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/85\" class=\"nounderline abstract_t\">Kim AR, Ulirsch JC, Wilmes S, et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation. Cell 2017; 168:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/86\" class=\"nounderline abstract_t\">Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/87\" class=\"nounderline abstract_t\">Abkowitz JL, Sabo KM, Nakamoto B, et al. Diamond-blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit. Blood 1991; 78:2198.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/88\" class=\"nounderline abstract_t\">Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991; 78:2203.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/89\" class=\"nounderline abstract_t\">Olivieri NF, Grunberger T, Ben-David Y, et al. Diamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus. Blood 1991; 78:2211.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/90\" class=\"nounderline abstract_t\">Nocka K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989; 3:816.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/91\" class=\"nounderline abstract_t\">Wu H, Klingm&uuml;ller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 1995; 377:242.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/92\" class=\"nounderline abstract_t\">Jubinsky PT, Krijanovski OI, Nathan DG, et al. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997; 90:1867.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/93\" class=\"nounderline abstract_t\">Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/94\" class=\"nounderline abstract_t\">Kurtz A, Jelkmann W, Bauer C. Insulin stimulates erythroid colony formation independently of erythropoietin. Br J Haematol 1983; 53:311.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/95\" class=\"nounderline abstract_t\">Yu J, Shao L, Vaughan J, et al. Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 1989; 73:952.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/96\" class=\"nounderline abstract_t\">Smith JC, Price BM, Van Nimmen K, Huylebroeck D. Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 1990; 345:729.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/97\" class=\"nounderline abstract_t\">Paulson RF. Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med 2014; 20:334.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/98\" class=\"nounderline abstract_t\">Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in &beta;-thalassemia. Nat Med 2014; 20:398.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/99\" class=\"nounderline abstract_t\">Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine &beta;-thalassemia. Blood 2014; 123:3864.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/100\" class=\"nounderline abstract_t\">Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24:744.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/101\" class=\"nounderline abstract_t\">Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol 2014; 165:870.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/102\" class=\"nounderline abstract_t\">Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 2014; 89:766.</a></li><li class=\"breakAll\">Piga AG, Perrotta SD, Melpignano A, et al. ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassemia: Preliminary results from a phase 2 study. Presented at the 56th Annual meeting of the American Society of Hematology, San Francisco CA, December 2014. </li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/104\" class=\"nounderline abstract_t\">Zhan M, Miller CP, Papayannopoulou T, et al. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007; 35:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/105\" class=\"nounderline abstract_t\">Zhao G, Yu D, Weiss MJ. MicroRNAs in erythropoiesis. Curr Opin Hematol 2010; 17:155.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/106\" class=\"nounderline abstract_t\">Zhang L, Flygare J, Wong P, et al. miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1. Genes Dev 2011; 25:119.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/107\" class=\"nounderline abstract_t\">Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005; 102:18081.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/108\" class=\"nounderline abstract_t\">Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14:843.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/109\" class=\"nounderline abstract_t\">Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008; 36:1585.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/110\" class=\"nounderline abstract_t\">Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A 2008; 105:3333.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/111\" class=\"nounderline abstract_t\">Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells 2010; 28:287.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/112\" class=\"nounderline abstract_t\">Pase L, Layton JE, Kloosterman WP, et al. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 2009; 113:1794.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/113\" class=\"nounderline abstract_t\">Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 2010; 24:1614.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/114\" class=\"nounderline abstract_t\">Yu D, dos Santos CO, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev 2010; 24:1620.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/115\" class=\"nounderline abstract_t\">Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72:449.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/116\" class=\"nounderline abstract_t\">Blanchard KL, Fandrey J, Goldberg MA, Bunn HF. Regulation of the erythropoietin gene. Stem Cells 1993; 11 Suppl 1:1.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/117\" class=\"nounderline abstract_t\">Porter DL, Goldberg MA. Regulation of erythropoietin production. Exp Hematol 1993; 21:399.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/118\" class=\"nounderline abstract_t\">Bunn HF, Gu J, Huang LE, et al. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998; 201:1197.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/119\" class=\"nounderline abstract_t\">Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/120\" class=\"nounderline abstract_t\">Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/121\" class=\"nounderline abstract_t\">Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/122\" class=\"nounderline abstract_t\">Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/123\" class=\"nounderline abstract_t\">Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95:7987.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/124\" class=\"nounderline abstract_t\">Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/125\" class=\"nounderline abstract_t\">Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/126\" class=\"nounderline abstract_t\">Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107:1.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/127\" class=\"nounderline abstract_t\">Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/128\" class=\"nounderline abstract_t\">Zhu H, Bunn HF. Signal transduction. How do cells sense oxygen? Science 2001; 292:449.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/129\" class=\"nounderline abstract_t\">Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/130\" class=\"nounderline abstract_t\">Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/131\" class=\"nounderline abstract_t\">Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/132\" class=\"nounderline abstract_t\">Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/133\" class=\"nounderline abstract_t\">Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005; 105:3133.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/134\" class=\"nounderline abstract_t\">Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 2009; 119:3373.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/135\" class=\"nounderline abstract_t\">Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/136\" class=\"nounderline abstract_t\">Wykoff CC, Sotiriou C, Cockman ME, et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 2004; 90:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/137\" class=\"nounderline abstract_t\">Rathmell WK, Simon MC. VHL: oxygen sensing and vasculogenesis. J Thromb Haemost 2005; 3:2627.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/138\" class=\"nounderline abstract_t\">Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105:659.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/139\" class=\"nounderline abstract_t\">Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/140\" class=\"nounderline abstract_t\">Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103:691.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/141\" class=\"nounderline abstract_t\">Semenza GL, Koury ST, Nejfelt MK, et al. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A 1991; 88:8725.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/142\" class=\"nounderline abstract_t\">Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992; 12:5373.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/143\" class=\"nounderline abstract_t\">Galson DL, Tsuchiya T, Tendler DS, et al. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995; 15:2135.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/144\" class=\"nounderline abstract_t\">Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996; 93:12969.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/145\" class=\"nounderline abstract_t\">Frede S, Freitag P, Geuting L, et al. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011; 117:4905.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/146\" class=\"nounderline abstract_t\">GRANT WC, ROOT WS. Fundamental stimulus for erythropoiesis. Physiol Rev 1952; 32:449.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/147\" class=\"nounderline abstract_t\">D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989; 57:277.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/148\" class=\"nounderline abstract_t\">Krantz SB, Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci U S A 1984; 81:7574.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/149\" class=\"nounderline abstract_t\">Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989; 74:103.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/150\" class=\"nounderline abstract_t\">Sawada K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988; 137:337.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/151\" class=\"nounderline abstract_t\">Akahane K, Tojo A, Fukamachi H, et al. Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions. Exp Hematol 1989; 17:177.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/152\" class=\"nounderline abstract_t\">ALPEN EL, CRANMORE D. Cellular kinetics and iron utilization in bone marrow as observed by Fe59 radioautography. Ann N Y Acad Sci 1959; 77:753.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/153\" class=\"nounderline abstract_t\">Macklis RM, Javid J, Lipton JM, et al. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest 1982; 70:752.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/154\" class=\"nounderline abstract_t\">Friedman AD, Linch DC, Miller B, et al. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest 1985; 75:1359.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/155\" class=\"nounderline abstract_t\">Dover GJ, Boyer SH, Zinkham WH. Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes. J Clin Invest 1979; 63:173.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/156\" class=\"nounderline abstract_t\">Kidoguchi K, Ogawa M, Karam JD, Martin AG. Augmentation of fetal hemoglobin (HbF) synthesis in culture by human erythropoietic precursors in the marrow and peripheral blood: studies in sickle cell anemia and nonhemoglobinopathic adults. Blood 1978; 52:1115.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/157\" class=\"nounderline abstract_t\">Clarke BJ, Nathan DG, Alter BP, et al. Hemoglobin synthesis in human BFU-E and CFU-E-derived erythroid colonies. Blood 1979; 54:805.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/158\" class=\"nounderline abstract_t\">Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci U S A 1977; 74:2923.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/159\" class=\"nounderline abstract_t\">Harandi OF, Hedge S, Wu DC, et al. Murine erythroid short-term radioprotection requires a BMP4-dependent, self-renewing population of stress erythroid progenitors. J Clin Invest 2010; 120:4507.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/160\" class=\"nounderline abstract_t\">Perry JM, Harandi OF, Porayette P, et al. Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling. Blood 2009; 113:911.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/161\" class=\"nounderline abstract_t\">Mangan KF, Chikkappa G, Bieler LZ, et al. Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood 1982; 59:990.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/162\" class=\"nounderline abstract_t\">Torok-Storb B, Martin PJ, Hansen JA. Regulation of in vitro erythropoiesis by normal T cells: evidence for two T-cell subsets with opposing function. Blood 1981; 58:171.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/163\" class=\"nounderline abstract_t\">Lipton JM, Smith BR, et al. Suppression of in vitro erythropoiesis by a subset of large granular lymphocytes. Blood 1984; 64:337a.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/164\" class=\"nounderline abstract_t\">Hoffman R, Kopel S, Hsu SD, et al. T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 1978; 52:255.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/165\" class=\"nounderline abstract_t\">Bagby GC Jr. T lymphocytes involved in inhibition of granulopoiesis in two neutropenic patients are of the cytotoxic/suppressor (T3+T8+) subset. J Clin Invest 1981; 68:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/166\" class=\"nounderline abstract_t\">Abdou NI, NaPombejara C, Balentine L, Abdou NL. Suppressor cell-mediated neutropenia in Felty's syndrome. J Clin Invest 1978; 61:738.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/167\" class=\"nounderline abstract_t\">Sugimoto M, Wakabayashi Y, Shiokawa Y, Takaku F. Effect of peripheral blood lymphocytes from systemic lupus erythematosus patients on human bone marrow granulocyte precursor cells (colony-forming units in culture). Stem Cells 1982; 2:164.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/168\" class=\"nounderline abstract_t\">Bom-van Noorloos AA, Pegels HG, van Oers RH, et al. Proliferation of T gamma cells with killer-cell activity in two patients with neutropenia and recurrent infections. N Engl J Med 1980; 302:933.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/169\" class=\"nounderline abstract_t\">Linch DC, Cawley JC, MacDonald SM, et al. Acquired pure red-cell aplasia associated with an increase of T cells bearing receptors for the Fc of IgG. Acta Haematol 1981; 65:270.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/170\" class=\"nounderline abstract_t\">Lipton JM, Nadler LM, Canellos GP, et al. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest 1983; 72:694.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/171\" class=\"nounderline abstract_t\">Torok-Storb BJ, Sieff C, Storb R, et al. In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization. Blood 1980; 55:211.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/172\" class=\"nounderline abstract_t\">Bacigalupo A, Podest&agrave; M, Mingari MC, et al. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol 1980; 125:1449.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/173\" class=\"nounderline abstract_t\">Smith BR, Lipton JM, et al. Multiparameter flow cytometric characterization of a unique T-lymphocyte subclass associated with granulocytopenia and pure red cell aplasia. Blood 1984; 64:343a.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/174\" class=\"nounderline abstract_t\">Torok-Storb B, Hansen JA. Modulation of in vitro BFU-E growth by normal Ia-positive T cells is restricted by HLA-DR. Nature 1982; 298:473.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/175\" class=\"nounderline abstract_t\">Falkenburg JH, Jansen J, van der Vaart-Duinkerken N, et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood 1984; 63:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/176\" class=\"nounderline abstract_t\">Sieff C, Bicknell D, Caine G, et al. Changes in cell surface antigen expression during hemopoietic differentiation. Blood 1982; 60:703.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/177\" class=\"nounderline abstract_t\">Sparrow RL, Williams N. The pattern of HLA-DR and HLA-DQ antigen expression on clonable subpopulations of human myeloid progenitor cells. Blood 1986; 67:379.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/178\" class=\"nounderline abstract_t\">Burdach SE, Levitt LJ. Receptor-specific inhibition of bone marrow erythropoiesis by recombinant DNA-derived interleukin-2. Blood 1987; 69:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/179\" class=\"nounderline abstract_t\">de Bruin AM, Voermans C, Nolte MA. Impact of interferon-&gamma; on hematopoiesis. Blood 2014; 124:2479.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/180\" class=\"nounderline abstract_t\">Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995; 162:134.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/181\" class=\"nounderline abstract_t\">Burdach S, Shatsky M, Wagenhorst B, Levitt L. The T-cell CD2 determinant mediates inhibition of erythropoiesis by the lymphokine cascade. Blood 1988; 72:770.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/182\" class=\"nounderline abstract_t\">Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15:928.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/183\" class=\"nounderline abstract_t\">Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136:4487.</a></li><li><a href=\"https://www.uptodate.com/contents/regulation-of-erythropoiesis/abstract/184\" class=\"nounderline abstract_t\">Furmanski P, Johnson CS. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 1990; 75:2328.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7161 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20133062\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H50387\" id=\"outline-link-H50387\">OVERVIEW OF ERYTHROPOIESIS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ERYTHROID PROGENITOR CELLS</a><ul><li><a href=\"#H11334197\" id=\"outline-link-H11334197\">Erythroid burst-forming unit</a></li><li><a href=\"#H11334203\" id=\"outline-link-H11334203\">Erythroid colony-forming unit</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">PRECURSORS AND MATURE CELLS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Acute anemia</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">STROMA</a><ul><li><a href=\"#H2516876\" id=\"outline-link-H2516876\">Macrophages</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">TRANSCRIPTION FACTORS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Tal-1/SCL</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Rbtn2/LMO2</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">GATA2</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">GATA1</a></li><li><a href=\"#H64529318\" id=\"outline-link-H64529318\">Kr&#971;ppel-like factor 1</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">GROWTH FACTORS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Erythropoietin</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Stem Cell Factor</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">IL-3 and GM-CSF</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Insulin and insulin-like growth factor I</a></li><li><a href=\"#H24105025\" id=\"outline-link-H24105025\">TGF-beta gene family</a><ul><li><a href=\"#H582791\" id=\"outline-link-H582791\">- Activin receptor ligand traps</a><ul><li><a href=\"#H582797\" id=\"outline-link-H582797\">Clinical utility</a></li></ul></li></ul></li></ul></li><li><a href=\"#H1280406\" id=\"outline-link-H1280406\">MicroRNAs</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">HYPOXIA AND EPO EXPRESSION</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">Hypoxia-inducible factor and the response to hypoxia</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">- Hepatocyte nuclear factor 4 and p300</a></li></ul></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">STRESS AND ERYTHROPOIESIS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">NEGATIVE REGULATION</a></li><li><a href=\"#H20133062\" id=\"outline-link-H20133062\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7161|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/70092\" class=\"graphic graphic_figure\">- Regulation of erythropoiesis</a></li><li><a href=\"image.htm?imageKey=HEME/55127\" class=\"graphic graphic_figure\">- Erythroid maturation sequence</a></li><li><a href=\"image.htm?imageKey=HEME/61552\" class=\"graphic graphic_figure\">- Reticulocyte shift</a></li><li><a href=\"image.htm?imageKey=HEME/53801\" class=\"graphic graphic_figure\">- Oxygen sensor model</a></li><li><a href=\"image.htm?imageKey=HEME/53916\" class=\"graphic graphic_figure\">- Serum EPO and anemia</a></li></ul></li><li><div id=\"HEME/7161|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/68933\" class=\"graphic graphic_picture\">- Erythroid precursors marrow</a></li><li><a href=\"image.htm?imageKey=HEME/71989\" class=\"graphic graphic_picture\">- Basophilic stippling</a></li><li><a href=\"image.htm?imageKey=HEME/73790\" class=\"graphic graphic_picture\">- Heinz body hemolytic anemia</a></li><li><a href=\"image.htm?imageKey=HEME/60588\" class=\"graphic graphic_picture\">- Howell-Jolly bodies</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production\" class=\"medical medical_review\">Anemia in children due to decreased red blood cell production</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-neutropenia\" class=\"medical medical_review\">Congenital neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia\" class=\"medical medical_review\">Diagnostic approach to the patient with polycythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=down-syndrome-clinical-features-and-diagnosis\" class=\"medical medical_review\">Down syndrome: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fetal-hemoglobin-hemoglobin-f-in-health-and-disease\" class=\"medical medical_review\">Fetal hemoglobin (hemoglobin F) in health and disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hyporesponse-to-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease\" class=\"medical medical_review\">Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-the-thalassemias\" class=\"medical medical_review\">Management and prognosis of the thalassemias</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=megakaryocyte-biology-and-the-production-of-platelets\" class=\"medical medical_review\">Megakaryocyte biology and the production of platelets</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mendelian-susceptibility-to-mycobacterial-diseases-specific-defects\" class=\"medical medical_review\">Mendelian susceptibility to mycobacterial diseases: Specific defects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease\" class=\"medical medical_review\">Molecular biology and pathogenesis of von Hippel-Lindau disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecular-pathogenesis-of-congenital-polycythemic-disorders-and-polycythemia-vera\" class=\"medical medical_review\">Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nk-cell-deficiency-syndromes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">NK cell deficiency syndromes: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-angiogenesis-inhibitors\" class=\"medical medical_review\">Overview of angiogenesis inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">Overview of hematopoietic stem cells</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=red-blood-cell-survival-normal-values-and-measurement\" class=\"medical medical_review\">Red blood cell survival: Normal values and measurement</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-iron-balance\" class=\"medical medical_review\">Regulation of iron balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=structure-and-function-of-normal-hemoglobins\" class=\"medical medical_review\">Structure and function of normal hemoglobins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-anemia-in-nondialysis-chronic-kidney-disease\" class=\"medical medical_review\">Treatment of anemia in nondialysis chronic kidney disease</a></li></ul></div></div>","javascript":null}